Investigation of usability and efficacy of loratadine rapidly disintegrating tablets (Claritin® Reditabs®)

A questionnaire survey on the usability and efficacy of loratadine rapidly disintegrating tablets (Claritin® Reditabs®) was conducted in 64 patients with pruritic skin disease (17 with urticaria, 25 with atopic dermatitis, and 22 with other eczema/dermatitis). Regarding overall ease of ingestion, 54 patients (84.4%) considered it "good", 9 (14.1%) "neither good nor bad", and 0 (0%) "bad". Eleven patients (17.2%) sometimes "forgot to take" the drug and 53 (82.8%) did not forget to take the drug, with a significantly lower number of patinets "forgetting to take" the drug. Fifty-four patients (84.4%) stated that they wanted to continue the drug. The reasons for wanting to continue it (with multiple answers allowed) included "it is convenient to take the drug anywhere" for 28 patients (43.8%), "no need for water" for 25 (39.1%), and "once-daily ingestion" for 23 (35.9%). It was found that the rapidly disintegrating tablet dosage form improved drug compliance.